One Biosciences partners with Assistance Publique – Hôpitaux de Paris (AP-HP) for a kidney disease research initiative. Focused on a rare kidney condition lacking viable therapeutic options, the collaboration grants One Biosciences access to anonymized patient samples and clinical data from four AP-HP hospitals. Leveraging its AI-driven single-cell analysis platform, One Biosciences aims to identify new therapeutic targets and biomarkers for disease relapse. The partnership, aligned with AP-HP’s @Hôtel-Dieu initiative, underscores the commitment to accelerating innovation for patient benefit within the French biotech ecosystem.
One Biosciences, a biotech company leveraging the power of single-cell analysis and A.I. to identify a new generation of precision medicine targets and treatments, announced today a partnership with Assistance Publique – Hôpitaux de Paris (AP-HP), a consortium of nearly all hospitals in the greater Paris region, to carry out a kidney disease research project. A condition characterized by a gradual loss of kidney function over time, this particular disease has no viable therapeutic option to date and transplantation is often the only alternative, despite frequent relapses.
As part of this research partnership, One Biosciences will be able to access anonymized patient samples and clinical data, from four of AP-HP’s hospitals (Hôpital Tenon, Hôpital Necker, Hôpital Kremlin-Bicêtre, Hôpitaux Universitaires Henri-Mondor). One Biosciences will leverage the data to identify new therapeutic targets in this rare kidney disease in order to develop precision medicines and biomarkers of a relapse of the disease via its discovery platform. One Biosciences’ unique discovery engine combines AI & single-cell technologies through a full suite of single-cell protocols & proprietary computational solutions and meets the highest standards of patient health data privacy and security.
“This partnership once again confirms the strength of the French innovation ecosystem in biotech and the synergies that are being forged between its players. Today, One Biosciences is joining forces with AP-HP, at the heart of Biolabs Hôtel Dieu, to accelerate research into the origins of a rare kidney disease in order to identify biomarkers and potential therapeutic targets to meet a very strong need of patients who today have no satisfactory treatment. This is an important milestone, and I’d like to thank our partners for their commitment,” said Hedi Ben Brahim, CEO of One Biosciences.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Nicolas Castoldi, Executive Director of the @Hôtel-Dieu initiative at AP-HP, explained that “This partnership with One Biosciences is a perfect example of the dynamic we want to build as part of the @Hôtel-Dieu initiative, by reinforcing the links between the most promising start-ups and AP-HP, accelerating the pace of innovation for the direct benefit of patients.”
One Biosciences is a French company spun out of Institut Curie and venture builder Home Biosciences, and is housed at Biolabs Hôtel-Dieu, a major open innovation facility for healthcare – recently opened in Paris’ oldest hospital site and connected to all 38 of AP-HP’s hospitals. This announcement marks One Biosciences’ commitment to a long-term partnership with AP-HP, encouraging the emergence of new solutions and technologies for the benefit of patients.
This project is led by Pr Laurent Mesnard, Head of Nephrological and Acute Kidney Intensive Care Service (SinRA), Hôpital Tenon, Nephrology Department AP-HP, Sorbonne University, with the support of Pr Julien Zuber, Hôpital Necker-Enfants malades AP-HP; Pr Vincent Audard, Hôpitaux Universitaires Henri-Mondor AP-HP (coordinator of the Center of Reference for Rare Disease dedicated to Idiopathic Nephrotic Syndrome and extra-membranous glomerulonephritis) and Pr Renaud Snanoudj, Hôpital Bicêtre AP-HP.